NCT03177746UnknownPhase 4
The Safety of Dapoxetine/Tadalafil Combination Therapy in Treatment of Men With Premature Ejaculation and Erectile Dysfunction
Neutec Ar-Ge San ve Tic A.Ş1 site in 1 country40 target enrollmentStarted: December 31, 2022Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Sponsor
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Evaluation of safety of study drug
Study Overview
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of Dapoxetine/Tadalafil 30/20 mg film-coated tablet in the treatment of men with premature ejaculation and erectile dysfunction.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 64 Years (Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18-64 years old men,
- •Participants must be heterosexual males and in a stable monogamous sexual relationship with a female partner for at least 6 months and will continue throughout the study,
- •Clinical diagnosis of erectile dysfunction, IIEF score ≤21,
- •Premature Ejaculation Diagnostic Tool (PEDT) score must be ≥11
- •Patients with life-long PE and acquired PE according to the description of International Society for Sexual Medicine (ISSM) ,
- •The patient and his partner must have sexual intercourse twice a week for the duration of the study,
- •Commitment to comply with the study protocol,
- •Patients who sign informed consent form (ICF).
Exclusion Criteria
- •History of medical events such as surgical interventions or neurologic conditions (e.g., multiple sclerosis), trauma, or infections that are associated with the development of symptoms of premature ejaculation (PE) and considered a potential cause of PE,
- •Having genital abnormalities, except penile curvature unless not prevent sexual intercourse,
- •Developed erectile dysfunction or premature ejaculation due to drug use or quit taking drugs,
- •Any conditions that prevent sexual intercourse with partners
- •History of epilepsy,
- •Severe renal insufficiency,
- •Liver disease,
- •History of in last 6 months stroke, myocard infarction, cardiac insufficiency (New York Cardiovascular Associates (NYCA) phase II-IV), atrioventricular block or message disorder such as sick sinus syndrome, severe ischemic cardiac disease, syncope, unstable angina, life-threatening arrhythmia or hypotension,
- •Non-Arteritic Anterior ischemic optic neuropathy,
- •Patients who are not eligible to have sexual intercourse due to existing health problems,
- •Autonomic neuropathy, retinitis pigmentosa, blood diseases, active peptic ulcer, abnormalities in ECG, severe systemic disease that cannot be controlled,
- •Systolic/Diastolic blood pressure at rest <90/50 mmHg and 170/100 mmHg<
- •History of allergy to Selective Serotonin Reuptake Inhibitor (SSRI) and phosphodiesterase inhibitor drugs,
- •Continuing to use or quitted in last 3 months of Monoamine oxidase inhibitor (MAOI), Thioridazine, Serotonin Reuptake Inhibitor (SSRI), Selective-norepinephrine Reuptake Inhibitor (SNRI), Serotonergic drug/herbal product, tricyclic antidepressant and atypical antipsychotic drugs,
- •Use of nitrates, alfa blockers, vasodilators, ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazodone, nelfinavir, atazanavir, cimetidine, erythromycin, clarithromycin, fluconazole, amprenavir, fosamprenavir, aprepitant, verapamil, diltiazem, any kind of vasodilator, antiplatelet, anticoagulant, dapoxetine, phosphodiesterase 5 inhibitor, alcohol and stimulant drug,
- •Patients on a different therapy (behavioral therapy or other drugs that are applied locally) for PE treatment
- •During the study, the possibility of taking medication which may affect the study drug's pharmacokinetic/pharmacodynamic properties
- •Patients who are defining symptoms of prostatitis clinically
- •Thyroid hormone disorders
Arms & Interventions
Dapoxetine/Tadalafil 30/20 mg film coated tablet
Experimental
Intervention: Dapoxetine/Tadalafil 30/20 mg film coated tablet (Drug)
Outcomes
Primary Outcomes
Evaluation of safety of study drug
Time Frame: 4 weeks
Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
Secondary Outcomes
- Evaluation of change in Intra-vaginal Ejaculation Latency Time (IELT) compared to baseline(4 weeks)
- Evaluation of premature ejaculation symptom scores compared to baseline(4 weeks)
- Evaluation of IIEF-15 (International Index of Erectile Function) score compared to baseline(4 weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
The Efficacy and Safety of Dapoxetine/Sildenafil Combination TherapyErectile DysfunctionPremature EjaculationNCT02939495Neutec Ar-Ge San ve Tic A.Ş75
Completed
Phase 3
Evaluation of the Clinical Efficacy and Safety of Dapoxetine, Combined Dapoxetine With Folic Acid and Combined Dapoxetine With Vitamin B12 in Treatment of Patients With Premature EjaculationPremature EjaculationNCT04085354Sohag University120
Unknown
Phase 2
Efficacy and Safety of Tadalafil in Hemodialysis PatientsErectile DysfunctionNCT00334477University of Pernambuco60
Completed
Phase 3
Concomitant Use of PriLigy in Men Treated for Erectile DysfunctionErectile DysfunctionSexual DysfunctionNCT01063855Johnson & Johnson Pharmaceutical Research & Development, L.L.C.495
Completed
Phase 3
A Study to Assess the Efficacy of Tadalafil to Treat Erectile Dysfunction After Radiotherapy of Prostate CancerProstate CancerErectile DysfunctionNCT00122499Erasmus Medical Center